Short answer
Cogent Biosciences, Inc. (COGT) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$97M
- −35.2% YoY
- EPS (diluted)
- −$0.53
- −1.9% YoY
Source: XBRL data from the Cogent Biosciences, Inc. (COGT) Q1 2026 10-Q on SEC EDGAR. USD.
Cogent Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no product sales; limited collaboration revenue historically
- Net loss $97.4M vs $72.0M YoY; operating margin not meaningful for pre-revenue company
- R&D expense $75.4M vs $63.0M; G&A $28.2M vs $11.9M
- Cash, equivalents and marketable securities $866.4M; operating cash use $86.9M vs $66.5M
- ATM financing $45.7M; cash runway into 2028, planned U.S. launch second half 2026 pending approval
Risk Factors
- No newly added risk factors; company reported no material changes from its December 31, 2025 Form 10-K
- Carried-forward risks include additional unknown or currently immaterial risks potentially harming business, financial condition, or operating results
- No quarter-specific regulatory, legal, compliance, operational, competitive, market, or financial risk updates disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cogent Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.